GCGR agonists(Glucagon receptor agonists), GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Digestive System DisordersEndocrinology and Metabolic Disease

Active Indication

Metabolic dysfunction-associated steatotic liver diseaseDiabetes Mellitus, Type 2Obesity

Inactive Indication-

Originator Organization

Eli Lilly & Co.

Active Organization

Eli Lilly & Co.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Sequence Code 1142931834

Source: *****

Clinical Trials associated with Retatrutide

NCT07357415

/ RecruitingPhase 3

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

Start Date24 Jan 2026

Sponsor / Collaborator

Eli Lilly & Co.

NCT07232719

/ RecruitingPhase 3

A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.
Participation in the study will last about 65 weeks and may include about 18 visits.

Start Date17 Nov 2025

Sponsor / Collaborator

Eli Lilly & Co.

NCT07165028

/ RecruitingPhase 3

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression.
Once the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study.

Start Date15 Oct 2025

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with Retatrutide

100 Translational Medicine associated with Retatrutide

100 Patents (Medical) associated with Retatrutide

106

Literatures (Medical) associated with Retatrutide

01 Mar 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders

Review

Author: Ebrahimi Shahmabadi, Hasan ; Raza, Aun ; Boshrouyeh, Reza ; Alavi, Seyed Ebrahim

Dual and triple incretin-based therapies are transforming treatment for type 2 diabetes mellitus, obesity, and non-alcoholic fatty liver disease. By targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors, these agents enhance glycemic control, reduce body weight, and improve liver outcomes. Drugs like tirzepatide and retatrutide have shown unprecedented efficacy and tolerability. This review summarizes their mechanisms, clinical progress, and limitations, highlighting how dual and triple incretin agonists may extend or refine the therapeutic benefits established by current GLP-1-based therapies. While challenges remain in safety, accessibility, and long-term use, multi-target agonists represent a promising future in metabolic disease management.

01 Mar 2026·Endocrinology, diabetes & metabolism

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials

Review

Author: Raged Gharbia ; Ayah Abulehia ; Barbara Gisella Carranza Leon ; Doha Jaber ; Omar Ayesh ; Hamzeh Abugharbieh ; Lila H. Abu-Hilal ; Adham Itbaisha ; Thekrayat Asad ; Hazem Ayesh

ABSTRACT:

Introduction:

Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight‐reducing effects. Several investigational GRA‐based agents, including retatrutide, cotadutide, mazdutide, and survodutide, have reported promising results across early and mid‐phase clinical trials. This comprehensive meta‐analysis evaluates the efficacy and safety of these agents in individuals with type 2 diabetes, overweight, or obesity.

Methods:

PubMed, Cochrane, Embase, and Scopus databases were systematically searched. Fourteen randomised controlled trials meeting the inclusion criteria were analysed using frequentist network meta‐analysis. Random‐effects models were applied to assess mean differences (MD) in weight change, both absolute and percent changes, HbA1c, adverse events, and discontinuation due to adverse events. Heterogeneity was quantified using the I2 statistic.

Results:

Retatrutide demonstrated the greatest weight reduction versus placebo (MD −13.44 kg; 95% CI [−18.38, −8.51]), followed by survodutide (MD −10.74 kg; 95% CI [−15.68, −5.80]) and mazdutide (MD −6.47 kg; 95% CI [−10.71, −2.24]). Cotadutide showed the smallest and nonsignificant effect (MD −3.41 kg; 95% CI [−11.63, 4.81]). Regarding HbA1c reduction, retatrutide showed the largest effect, followed by survodutide, mazdutide, and cotadutide; however, only the effect of retatrutide reached statistical significance. In terms of safety, mazdutide demonstrated the most favourable tolerability profile, whereas retatrutide and cotadutide were associated with comparatively lower tolerability.

Conclusions:

Retatrutide and survodutide exhibit the most favourable efficacy profiles for obesity and T2DM, with acceptable safety. These findings support their potential clinical use and highlight the need for future head‐to‐head trials.

01 Jan 2026·Clinical Pharmacology in Drug Development

The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities

Review

Author: Ganamurali, Nila ; Sabarathinam, Sarvesh

Abstract:

Obesity has emerged as a global health crisis requiring innovative therapeutic strategies beyond conventional approaches. While glucagon‐like peptide‐1 (GLP‐1) and dual GIP/GLP‐1 receptor agonists have redefined pharmacological management, their limitations necessitate further innovation. Retatrutide (LY3437943), a novel triple agonist targeting GLP‐1, glucose‐dependent insulinotropic polypeptide (GIP), and glucagon receptors, represents a transformative advance in obesity pharmacotherapy. Phase 2 trials report unprecedented weight reductions, comparable to bariatric surgery, with additional benefits for metabolic comorbidities such as NASH and cardiovascular disease. Retatrutide exemplifies rational multi‐agonist peptide engineering and signals a paradigm shift in systems pharmacology. This perspective underscores the urgent need for scientific engagement, equity considerations, and policy preparedness, positioning retatrutide as a watershed in obesity treatment and a blueprint for future poly‐agonist therapies.

News (Medical) associated with Retatrutide

25 Mar 2026

·endpoints.news

Boehringer Ingelheim plans for dealmaking, obesity pipeline and R&D to counter US price pressure

Boehringer Ingelheim said it plans to keep up high levels of R&D spending, and could look at China-based companies for dealmaking, as key planks of its strategic approach this year, board chairman Shashank Deshpande said Wednesday. Deshpande was discussing the company’s 2025 performance on a call with members of the media. Last year, the German biopharma’s human drug sales grew 7.4% on a constant currency basis to €22.7 billion ($26.3 billion), and the company expects a similar trend this year. “We expect to grow this year on a comparable basis, adjusted for currency and extraordinary effects,” said Deshpande, who also heads Boehringer’s human pharma business unit. The company’s biggest money-makers in 2025 were once again its diabetes and heart drug Jardiance and the lung disease med Ofev. But sales in the US shrank 2% from 2024, hit by “quite substantial reductions in price” in the country. The Medicare prices of Jardiance, Ofev and the diabetes therapy Trajenta are all now negotiated under the IRA. If the impact on pricing in the US were to be excluded, finance chief Frank Hübler said, “we would have also grown there as we did in Europe and other regions.” The advent of new products could help. Boehringer has won two approvals so far this year, with the lung cancer treatment Hernexeos and the idiopathic pulmonary fibrosis drug Jascayd . It also has an obesity drug that’s drawing attention. Survodutide, which Boehringer licensed from Zealand Pharma, is in two pivotal trials, and data are due at the American Diabetes Association meeting in June. “I would expect to see good weight loss in the context of important effects on the general metabolic [health] and particularly the liver,” Boehringer’s head of innovation Paola Casarosa told Endpoints News in an interview. Pressed on what good weight loss might look like, she declined to name a target percentage, but suggested that Boehringer is focused on quality over quantity: It wants to see if patients retain more muscle than on other incretin drugs, Casarosa said. Side effect rates have also been a key differentiator for the class. The drug is unlikely to reach market before the second half of 2027 — and even that might be ambitious. How will Boehringer compete with Eli Lilly and Novo Nordisk, and possibly also new entrants such as Pfizer and Roche? “It would be sort of arrogant to expect, well, we’re going to have a molecule that’s completely different from anything else,” Casarosa said. But survodutide has the unusual mechanism of GLP-1 and glucagon agonism — making it a potentially unique approach in a world of drugs that either only target GLP-1, or go after a different set of targets. Casarosa said she hopes that its glucagon agonism could allow survodutide to be particularly useful for obesity patients who also have liver disease. Phase 3 trials in the fatty liver condition known as MASH are also due this year. Boehringer also revealed on Wednesday that another obesity asset, its triple agonist, will head into Phase 2 this year. The program is somewhat mysterious: Casarosa declined to confirm its exact mechanism, so it might not be what’s known as a triple-G — an agonist of GLP-1, GIP and glucagon — like Lilly’s retatrutide or Novo Nordisk’s UBT251 . “We are investing with full speed and energy to the next steps, because we see the potential to really have strong weight loss in the context of, in our hands, unprecedented tolerance,” Casarosa said of the drug, which is called BI 3034701. Boehringer is developing it in collaboration with the Danish biotech Gubra. Survodutide and the triple agonist entered Boehringer’s pipeline via partnering deals, and they won’t be the last assets to follow this path. The company is looking at collaboration opportunities in China, and intends to stay in its familiar therapeutic areas of cardiovascular-renal-metabolism, oncology, inflammation and respiratory, and mental and eye health. “We would be looking at innovation and how we can leverage the upcoming innovation in China, how we can leverage Chinese speed in development — but all through the lens of our existing research portfolio,” Deshpande said on the media call. Alongside external sources of new products, the company is committed to spending on in-house R&D. It now plows over 27% of its net pharmaceutical sales into R&D for human therapeutics. About 40 to 50% of Boehringer’s portfolio has some elements of external innovation, Casarosa said, whether acquisitions, licensing or use of external technologies to make the molecules. She also pointed out that through its corporate venture fund, Boehringer can help seed new technologies.

Phase 2Phase 3

25 Mar 2026

·www.fiercebiotech.com

Novo Nordisk prepares to go global as triple-G prospect passes midphase diabetes test in China

Novo Nordisk plans to start a global phase 2 trial of UBT251 in people with Type 2 diabetes in the second half of the year.\n Novo Nordisk and its Chinese partner have reported another midphase win for their triple-G candidate, sharing diabetes data to add to the momentum generated by an obesity readout. But, while the data suggest the asset is competitive, Eli Lilly’s head start in the space means it remains the company to beat. Last year, Novo paid The United Laboratories $200 million upfront for ex-China rights to UBT251. Like Lilly’s retatrutide, UBT251 is a triple agonist of the GLP-1, GIP and glucagon receptors. Clinical trials have shown triple-G agonists drive deeper weight loss than GLP-1 therapies such as Novo’s Wegovy and dual-target molecules including Lilly’s Zepbound. Wednesday, TUL shared evidence that UBT251 is more effective than semaglutide—the GLP-1 drug Novo sells as Ozempic and Wegovy—in people with Type 2 diabetes. The company’s United Biotechnology R&D unit generated the evidence in a phase 2 trial of 211 Chinese patients with Type 2 diabetes.After 24 weeks of once-weekly injections, levels of the blood sugar measure HbA1c fell up to 2.16% in the UBT251 cohorts, compared to declines of 1.77% on semaglutide and 0.66% on placebo. Mean HbA1c was 8.12% at baseline. Lilly saw HbA1c reductions of up to 2.02% at Week 24 of its phase 2 retatrutide trial in people with Type 2 diabetes. The company also recently reported HbA1c reductions of up to 1.9% in a larger and longer phase 3 trial of retatrutide.Novo and TUL reported mean body weight reductions of up to 9.8% in the UBT251 cohorts, versus 4.8% in the semaglutide group and 1.4% in the placebo arm. Lilly reported weight loss of up to 16.94% in its phase 2 trial, although at least some of the apparent advantage over UBT251 is explained by timing. The retatrutide trial measured weight loss at Week 36, compared to Week 24 in the UBT251 study.The UBT251 study evaluated 2-mg, 4-mg and 6-mg doses of the drug candidate. Patients on semaglutide received a 1-mg dose. In the real world, people taking semaglutide for diabetes start with a 0.25-mg pen and titrate to doses of up to 2 mg. Semaglutide is given at doses of up to 7.2 mg to treat obesity. Lilly tested retatrutide at doses of up to 12 mg in people with Type 2 diabetes. Encouraged by the Chinese data, Novo plans to start a global phase 2 trial of UBT251 in people with Type 2 diabetes in the second half of the year. The Danish drugmaker recently began a global phase 1b/2a trial in about 330 people who are overweight or with obesity. Novo expects top-line data from the weight loss trial in 2027. The timeline raises questions about UBT251’s commercial prospects. Lilly plans to file for FDA approval of retatrutide in obesity this year, with a diabetes submission scheduled to follow in 2027. If Lilly’s filings go to plan, retatrutide could come to market around the time Novo enters phase 3.Such considerations are coloring analysts’ expectations. Last month, BMO Capital Markets analysts said in a note to investors that the data on UBT251 in obesity “appear encouraging.” However, the analysts added that “with Novo significantly behind retatrutide\'s clinical development timeline, [the] results have less significance in the near term.”

Phase 2Clinical Result

25 Mar 2026

·www.biospace.com

Despite Novo’s Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs

iStock, happyphoton This year’s catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk is expecting more clinical data for next-gen weight loss asset CagriSema, which recently lost a head-to-head battle with Lilly’s Zepbound. Novo Nordisk’s Wegovy injection reeled in $12.5 billion in 2025, while Eli Lilly’s Zepbound took home $13.5 billion . However, according to BMO Capital Markets, they’re leaving money on the table. “Obesity med net pricing has declined significantly, but access remains difficult for some patients, preventing full uptake and usage among eligible patients,” BMO wrote in a Wednesday note following its third annual Metabolic Health Summit. The event, held Tuesday in New York, brought together pharma representatives from Novo and Lilly, along with Structure Therapeutics, Amgen, Pfizer and Corbus Pharmaceuticals. Healthcare was also well-represented, with ProCare RX, Ro Health and several physicians in attendance. Certainly, prices for the drugs have fallen over the past year. In November, Novo and Lilly struck a deal with the White House to offer their respective GLP-1s—Novo’s semaglutide, marketed as Wegovy for weight loss and Ozempic for type 2 diabetes, and Lilly’s tirzepatide, marketed as Zepbound and Mounjaro for the same indications, respectively—through President Donald Trump’s direct-to-consumer marketplace for about $350 per month. Under the deal, weight loss pills would be offered at $150 for the initial doses. Novo’s oral Wegovy launched in January, while Lilly’s orforglipron is currently under review at the FDA. Despite these price drops, however, BMO said access improvements have been limited over the past year. Oral options could start to improve access. BMO called the launch of the Wegovy pill “impressive,” adding that it is activating new patient segments. The product, approved just before Christmas 2025, got off to a strong start in January, reaching more than 3,000 patients in its first week. BMO in its Wednesday note attributed some of the pill’s early success to “an attractive entry cash price of $149,” combined with branding connection to the Wegovy injectable. Sales of the Wegovy portfolio are expected to increase from $13.5 billion in 2026 to $18.9 billion in 2031, with the pill contributing $2.76 billion, according to a recent GlobalData report . Obesity Novo Rises as Oral Wegovy Reaches Over 3,000 Patients in First Week of Launch Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales. January 19, 2026 · 1 min read · Tristan Manalac Read more Meanwhile, “Don’t rule out CagriSema just yet,” the analysts cautioned. Novo’s next-gen candidate, which combines semagutide with amylin agent cagrilintide, fell to Zepbound last month in a head-to-head trial , generating 23% weight loss compared to Zepbound’s 25.5%. “We view this as the worst case scenario for Novo Nordisk, though we do not believe there is material read-through to the amylin class more broadly,” William Blair analysts wrote in their own Wednesday morning note rounding up fourth quarter earnings updates from obesity companies they cover. But the BMO group said that Novo’s REDEFINE-11 Phase 3 study, which is expected to read out in the first half of 2027, could offer a better opportunity for investors to assess the efficacy of the next-gen combo weight loss treatment. BMO added that its key opinion leader “likes [CagriSema] too!” The FDA is expected to make a decision on CagriSema by the end of the year, according to William Blair. Weight loss Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the candidate stage, and the bet did not pay off. February 23, 2026 · 4 min read · Annalee Armstrong Read more On the Lilly front, near-term catalysts include a decision on orforglipron by April 10 plus a regulatory submission for retatrutide in overweight/obesity, the analysts said. BMO also noted that the Indianapolis-based pharma is studying its incretin therapies in the neuropsychiatric space for addiction and depression. This effort, the analysts wrote, “appears a moral imperative, but may be more challenging for clinical success.” Specifically, Lilly is evaluating brenipatide, which targets both the GLP-1 and GIP receptors, in two Phase 3 trials for alcohol use disorder and a Phase 2 study for relapse in tobacco use disorder. Another Phase 2 trial will test the drug in combination with other medicines in people with opioid use disorder. Lilly expects the trials to wrap in 2027 and 2028, a spokesperson told BioSpace earlier this month. BMO also gave a shoutout to Structure Therapeutics’ ACCG-2671 , a dual amylin and calcitonin receptor agonist currently in Phase 1 studies, writing that data expected during the second half of 2026 “could be a key development point for the company, demonstrating pipeline expansion beyond [lead candidate] aleniglipron.” Obesity Structure Climbs on ‘Highly Competitive’ Pro Weight Loss Pill Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial. The biotech is planning to launch a late-stage program for the drug later this year. March 16, 2026 · 2 min read · Tristan Manalac Read more BMO offered other key takeaways from the summit, including that care delivery models are starting to emphasize durability of treatment over headline weight loss, and that Medicaid access “remains tougher with recent cuts to the program.”

Phase 3Phase 2Drug ApprovalPhase 1

100 Deals associated with Retatrutide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metabolic dysfunction-associated steatotic liver disease	Phase 3	United States	Eli Lilly & Co.	18 Dec 2025
Metabolic dysfunction-associated steatotic liver disease	Phase 3	China	Eli Lilly & Co.	18 Dec 2025
Diabetes Mellitus, Type 2	Phase 3	United States	Eli Lilly & Co.	11 Jul 2023
Diabetes Mellitus, Type 2	Phase 3	Argentina	Eli Lilly & Co.	11 Jul 2023
Diabetes Mellitus, Type 2	Phase 3	Australia	Eli Lilly & Co.	11 Jul 2023
Diabetes Mellitus, Type 2	Phase 3	Brazil	Eli Lilly & Co.	11 Jul 2023
Diabetes Mellitus, Type 2	Phase 3	India	Eli Lilly & Co.	11 Jul 2023
Diabetes Mellitus, Type 2	Phase 3	Mexico	Eli Lilly & Co.	11 Jul 2023
Diabetes Mellitus, Type 2	Phase 3	Romania	Eli Lilly & Co.	11 Jul 2023
Diabetes Mellitus, Type 2	Phase 3	Spain	Eli Lilly & Co.	11 Jul 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06354660 (TRANSCEND-T2D-1, Company_Website) Manual	Phase 3	Diabetes Mellitus, Type 2	537	Retatrutide 4 mg	orjujlfugb(rpqfjynyxl) = fylpeojfkw ssjaagkdll (ctaviqwebm ) Met View more	Positive	19 Mar 2026
				Retatrutide 9 mg	orjujlfugb(rpqfjynyxl) = xvldfuhswi ssjaagkdll (ctaviqwebm ) Met View more
NCT05931367 (TRIUMPH-4, Company_Website) Manual	Phase 3	Overweight \| Obesity \| Osteoarthritis, Knee	445	Retatrutide 9 mg	eoscroyklh(cxpgivnlpn) = zyofumrbog souvuvimhk (nhgbjwhjep ) View more	Positive	11 Dec 2025
				Retatrutide 12 mg	eoscroyklh(cxpgivnlpn) = qodccfqsgs souvuvimhk (nhgbjwhjep ) View more
Pubmed Manual	Not Applicable	Overweight \| Obesity	15,491	Tirzepatide 15 mg once weekly	jvpvyldtcu(xvqegwwpnq) = gelhaubxrx pjcznpcypf (gnbugbvqew )	Positive	07 Jan 2025
				Semaglutide 2.4 mg once weekly	jvpvyldtcu(xvqegwwpnq) = hybtsjdygg pjcznpcypf (gnbugbvqew )
ADA2024	Phase 2	Diabetes Mellitus, Type 2	281	Retatrutide 8 mg	asacqlfdkm(xkfheaqdrb) = yeruuxkvdk jmtbhfwvpj (lsjbtlmztk ) View more	Positive	14 Jun 2024
				Retatrutide 12 mg	rmoppmixyq(kxasftrnyn) = qdmbxfckjj qikzbjnupo (osrlllzrla ) View more
NCT04881760 (Pubmed) Manual	Phase 2	Metabolic dysfunction-associated steatotic liver disease	98	Retatrutide 1 mg	lbflxlvqlb(tqrnruvxnr) = jgclqodxfh qzwulfkjqw (enqjzvrskg ) View more	Positive	10 Jun 2024
				Retatrutide 4 mg	lbflxlvqlb(tqrnruvxnr) = lvdbxujsfj qzwulfkjqw (enqjzvrskg ) View more
NCT04881760 (phase 2 trial, EASD2023)	Phase 2	Obesity Maintenance	338	Retatrutide 1 mg	wnxdnkjzpa(kfvzindliv) = Most common adverse events were gastrointestinal (nausea, diarrhoea, vomiting), were mild-to-moderate in severity, occurred primarily during dose-escalation, and were mitigated by a lower starting dose (2 mg vs 4 mg) yzjxhyiqqd (ytxrderzio )	Positive	03 Oct 2023
				Retatrutide 4 mg
NCT04867785 (EASD2023)	Phase 2	Diabetes Mellitus, Type 2	-	Retatrutide 0.5 mg	qaprdppxfd(xtiuxnqjfd) = pbccbiayjn sdwefpqfap (duhbfhkwjk )	Positive	03 Oct 2023
				Retatrutide 4 mg	qaprdppxfd(xtiuxnqjfd) = eakcenqrcp sdwefpqfap (duhbfhkwjk )
NCT04881760 (phase 2 trial \| COMMODORE 1, CTgov)	Phase 2	Obesity	338	Placebo (Placebo)	edyrrmluln(pfyprakmra) = bfvmffdpcy imvlnnukqw (mdgrxprlkc, 0.54) View more	-	13 Sep 2023
				LY3437943 (4 mg LY3437943 (2 mg))	edyrrmluln(pfyprakmra) = uvosnrwtvf imvlnnukqw (mdgrxprlkc, 0.71) View more
NCT04867785 (CTgov)	Phase 2	Diabetes Mellitus, Type 2	281	Placebo (Placebo)	cihmabryhq(cdpoivkhoh) = cxsffcetmj swkjkdycxx (rwoclvrctl, 0.21) View more	-	03 Jul 2023
				Dulaglutide (1.5 mg Dulaglutide)	cihmabryhq(cdpoivkhoh) = kzziahllsj swkjkdycxx (rwoclvrctl, 0.12)
NCT04881760 (Pubmed) Manual	Phase 2	Obesity	338	Retatrutide (1-mg group: 1 mg)	nrinuesqei(lblvxndakr) = cvanqqtqsu qrcqgklueo (fnkjiyllxs ) View more	Positive	26 Jun 2023
				Retatrutide (combined 4-mg group: 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg])	nrinuesqei(lblvxndakr) = pdlwaswxhs qrcqgklueo (fnkjiyllxs ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis